Heart attack survivors: can a Twice-Yearly shot melt artery plaque?
NCT ID NCT06372925
First seen Jan 27, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study tests whether inclisiran, a twice-yearly injection, can reduce fatty plaque buildup in heart arteries of people who recently had a heart attack and have high cholesterol. About 334 adults aged 18-75 will receive inclisiran or standard care, and doctors will use special imaging to measure plaque changes over one year. The goal is to see if this drug can better control artery disease and prevent future heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE, ATHEROSCLEROTIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGWuhan, Hubei, 430060, China
-
Novartis Investigative Site
RECRUITINGNanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
RECRUITINGChangchun, Jilin, 130033, China
-
Novartis Investigative Site
RECRUITINGDalian, Liaoning, 116023, China
-
Novartis Investigative Site
RECRUITINGJining, Shandong, 272000, China
-
Novartis Investigative Site
RECRUITINGXian, Shanxi, 710061, China
-
Novartis Investigative Site
RECRUITINGChengdu, Sichuan, 610072, China
-
Novartis Investigative Site
RECRUITINGWenzhou, Zhejiang, 325027, China
-
Novartis Investigative Site
RECRUITINGBeijing, 101149, China
-
Novartis Investigative Site
RECRUITINGLanzhou, 730000, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300000, China
-
Novartis Investigative Site
RECRUITINGHefei, Anhui, 230001, China
-
Novartis Investigative Site
RECRUITINGFuzhou, Fujian, 350001, China
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510030, China
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510080, China
-
Novartis Investigative Site
RECRUITINGShenzhen, Guangdong, 518000, China
-
Novartis Investigative Site
RECRUITINGZunyi, Guizhou, 563000, China
-
Novartis Investigative Site
RECRUITINGHarbin, Heilongjiang, 150086, China
-
Novartis Investigative Site
RECRUITINGZhengzhou, Henan, 450003, China
Conditions
Explore the condition pages connected to this study.